Clinical Trial

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

Study acronym: ENZARAD
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 6, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at high risk of recurrence.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2015-05-13; most recent amendment 2026-05-04.
Status change: Recruiting → Active, Not Recruiting 2018-07-03
Trial Details
NCT Number NCT02446444
Lead Sponsor University of Sydney
Collaborators: Australian and New Zealand Urogenital and Prostate Cancer Trials Group, National Health and Medical Research Council, Australia, Cancer Trials Ireland, Trans Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer - EORTC
Conditions Prostatic Neoplasms
Enrollment 802 participants
Start Date 2014-03
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-06